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ABSTRAK
Sel dendritik (Dendritic Cell, DC) merupakan antigen presenting cells (APC) utama yang merangsang sel T 
naïve sehingga mencetuskan respons imun adaptif. Penyakit Graves’ (Graves’ Disease, GD) merupakan penyakit 
autoimun yang ditandai adanya autoantibodi terhadap Thyroid Stimulating Hormone Receptor (TSHR), yang 
berikatan dengan TSHR dan merangsang produksi hormon tiroid. Sel dendritik masih merupakan APC utama 
pada respons imun GD, meskipun sel tirosit pada GD juga mengekspresikan molekul Major Histocompatibility 
Class (MHC) kelas II. Penelitian mengenai DC pada GD dilakukan dengan mengisolasi DC intra tiroid maupun 
DC di sirkulasi perifer. Hasil penelitian DC pada GD masih kontroversial. Ditemukannya perubahan jumlah 
dan profil DC pada GD menunjukkan adanya perubahan aktivitas respons imun dan gangguan sel T regulator 
(Treg) pada GD. 
Kata kunci: sel dendritik, penyakit Graves.
ABSTRACT
Dendritic cells are major antigen-presenting cells (APC) that stimulate naïve T cells, which induce 
adaptive immune responses. Graves’ disease (GD) is an autoimmune disease characterized by the presence of 
autoantibodies against Thyroid Stimulating Hormone Receptor (TSHR). The autoantibodies bind with TSHR 
and stimulate thyroid hormone production. Dendritic cells are still the major APC in GD immune response 
although thyrocytes in GD can also express Major Histocompatibility Class (MHC) class II molecule. Studies 
about DC in GD have been conducted by isolating intra-thyroid DC or DC in peripheral circulation. Results 
of DC studies in GD are still controversial. Changes in number and profile of DC are found, which indicate 
altered immune response activity and defects of regulator T cell (Treg) in GD.
Key words: dendritic cells, Graves’ disease.
INTRODUCTION 
Approximately, 60-90% thyrotoxicosis is 
caused by GD.1 Graves’ disease is an autoimmune 
disorder of the thyroid gland (Autoimmune 
Thyroid Disease, AITD) and characterized 
by the production of autoantibodies. These 
autoantibodies then bind with TSHR and 
increase the synthesis of thyroid hormones. 
Out of the three thyroid autoantigens, i.e. the 
thyroglobulin (Tg), thyroid peroxidase (TPO) 
and TSHR, TSHR is the major autoantigen for 
Graves’ disease, in which approximately 80-
100% patients with untreated GD have TSHR 
antibodies.1,2
Graves’ disease develops due to a complex 
interaction between genetic and environmental 
factors. Gene polymorphism, either genes 
associated with immune response or specific 
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gene for thyroid gland, can affect the incidence 
of GD. Enviromental factors that have roles 
in pathogenesis of GD include physical stress, 
gender, radiation exposure, iodium intake and 
hormonal changes (post-partum period).1
In contrast to thyroid cells in normal subjects, 
thyroid cell in AITD expresses MHC class II 
molecules ((HLA-DR, DP and DQ); therefore, it 
has APC characteristics and potently stimulates 
T cells as well as induces the adaptive immune 
reaction. However, in order to be able to activate 
the naïve T cells, in addition to the class II MHC, 
the costimulatory molecules are also required. 
Although they express the class II MHC, but the 
thyroctes do not have costimulatory molecules; 
therefore, they can not stimulate naïve T 
lymphocyte cells (non-professional APC).1,2
Initial immune response in GD requires 
two signals, i.e. the specific and unspecific 
signal. Specific signal comes from exogenous 
or endogenous Ag; while the non-specific 
signal is a signal of costimulatory molecule and 
inflammatory cytokines. Endogenous antigen 
may be in the form of TSHR (the major form) and 
dead thyrocytes, which undergo apoptosis; while 
exogenous Ag may include viruses or bacteria. 
TSH receptor experiences post-translational 
cleavage and results in 2 subunit structures; the 
subunit A is separated and will have a function 
as autoantigen. Autoantigen will be engulfed and 
processed by professional APC, i.e. macrophage 
and DC, into peptides. The peptides are then 
bound to intracellular MHC molecule into a 
complex molecule of MHC-peptide, which is 
transferred to cell surface by APC transporter. 
Adaptive immune responses in GD commences 
when DC present the complex molecule of MHC-
peptide to the naïve T cell.3,4 In the initial phase, 
the T cell through the T Cell Receptor (TCR) on its 
surface interacts with the MHC-peptide complex 
on the DC (APC).  After this phase, the naïve T cell 
needs further signal for activation process. The 
next step is the interaction between CD28 on the 
surface of T cell and costimulatory molecules of 
CD80 and CD86 on the surface of DC (APC). The 
presence of both signals (TCR binding with MHC-
peptides and binding between CD28 and CD 80/
CD86) will activate the naïve T cell. The activated 
naïve T cell will proliferate and produce cytokines, 
which activate the next cascades of immune 
response resulting in stimulating autoantibodies, 
which are produced by B lymphocytes. In GD, 
TSHR stimulating antibodies will induce TSHR 
to increase the synthesis of thyroid hormones, 
synthesis of thyroglobulin, increase iodium intake, 
protein synthesis and the development of thyroid 
cells that may lead to hyperthyroidism.1, 2,5
DENDRITIC CELLS 
Dendritic cells are components of immune 
cells that become connectors between innate 
and adaptive immune responses. The number of 
circulating DC ranges between 0.5 - 2% of the 
Peripheral Blood Mononuclear Cells (PBMCs). 
Dendritic cells originate from multipotent 
hematopoietic stem cells. Based on the type of 
receptor on its surface, there are tyo types of DC. 
The first is mDC (myeloid DC/conventional DC), 
which expresses CD11c+ CD123lo or CD11clo 
CD123- and derived from myeloid pathway; 
while the second type is pDC (plasmacytoid 
DC), which expresses CD11c-CD123hi and 
derived from lymphoid pathway. Both types of 
DC (mDC and pDC) have some differences in 
several aspects, including the ability of antigen 
uptake, the profile of secreted cytokines, the role 
on immune responses and tolerance.6
Plasmacytoid DC are mainly found in 
peripheral blood and lymphoid organs, which 
have the ability to response self-nucleic acid 
or virus through the toll-like receptor (TLR)7 
and TLR-9 by producing IFN-α and other 
proinflammatory cytokines abundantly; therefore, 
they have role in autoimmune process and innate 
antiviral immunity. In contrast, mDCs mainly 
produce proinflammatory cytokines of IL-12 
and TNF-α, which elicit responses to microbial 
stimulation. In addition to pDCs and mDCs, there 
are also other types of DC, i.e. the DC precursors 
(CD14+ monocytes) and CD1a+CD11+, the 
precursors of Langerhans cells.7,8
After leaving the bone marrow, DC 
precursors enter the blood vessel and stay in 
several tissues waiting for Ag stimulation. In 
the tissues, DC precursors change into iDC 
(immature DC), which expresses MHC class 
I and class II and low-density costimulatory 
molecules. Immature DCs can respond to 
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their microenvironment and are able to have 
direct interaction with microorganism through 
patern recognition receptors (PARP), which is 
similar to the TLR and subsequently capture 
antigen via macropinocytosis or apoptosis of 
cell bodies through phagocytosis. They also 
express inflammatory chemokine receptors such 
as CCR2, CCR5, CCR6, CXCR1 and CXCR2; 
therefore, the immature DCs can respond to 
inflammatory chemokines produced by immune 
cells at inflammatory site. When they receive 
appropriate chemokine stimulation, iDCs will 
leave the tissues and enter lymphatic circulation, 
then migrating to the T cell are of the lymph node, 
they subsequently convert to mature DC (DC) 
and ready to interact with T lymphocyte cells. 
Mature dendritic cells express MHC class I and 
II and high-density costimulatory molecules; 
thus, they have a very strong APC capability.8-10
TOLERANCE AND AUTOIMMUNITY: THE 
ROLE OF DENDRITIC CELLS AND T-REG 
CELLS
In normal condition, the body immune 
response can recognize and generate tolerance 
to self-antigens. The ability of immune response 
in tolerating self-antigen is elicited by a 
combination between the central and peripheral 
tolerance. The central process is characterized 
by diminished immature T cells in the thymus 
gland and the process indeed has a main role 
on eliminating the autoreactive T cells. Thyroid 
autoantigens such as TSHR, Tg and TPO 
are expressed by epithelial cells of thymus 
gland and the expression of autoantigens is 
controlled by Autoimmune Regulator (AIRE) 
gene. Autoreactive T cell stimulated by thyroid 
autoantigen should be destroyed or paralyzed in 
the thymus, but if autoreactive T cells manage 
to escape, then the peripheral mechanism will 
take over.1
In peripheral tolerance, DCs is in steady state 
condition (before any infection and inflammation 
occurs) and they are immature. Immature 
DC (iDC) will circulate thorugh the tissues 
and thyroid glands, capturing self-antigens or 
harmless foreign protein.11
Several studies have shown the role of DCs on 
both direct and indirect mechanism of peripheral 
tolerance. In direct mechanism, DCs can cause 
diminished autoreactive T cells by producing 
tryptophan metabolites or signaling through 
CD95. The indirect mechanism is via immature 
DCs, which have tolerogenic characteristic that 
can stimulate the Treg cells. The last mechanism 
is more effective for developing memory in 
the tolerance process and suppressing immune 
response (immunoresponsive) to certain antigen 
in long period of time.11
In steady state condition, i.e. without any 
inflammation or infection, the iDCs will be able 
to recognize self antigen or weak foreign AG 
and subsequently develop tolerance against the 
(self) Ag. This stage is very essential because DC 
must be able to differentiate the self antigen from 
the strong foreign antigen, when the infection 
occurs someday. When there is any inflammation 
or infection, the environment changes due to 
the production of inflammatory cytokines; 
therefore, it stimulates iDc maturation. Mature 
DC is a very strong APC; therefore, the exposure 
of self antigen on mature DC can induce the 
immune response cascade, or in other words, 
there is failure of tolerance against self antigen.8 
However, if the stage of tolerance process against 
self antigen occurs before the infection, then 
the immune response to this self antigen can be 
prevented.12 Multiple iDC exposure on T cells 
may also increase the proportion of Treg cell 
and subsequently it may suppress the activity of 
T cells and B cells; therefore, the production of 
antibody is suppressed. In addition, Treg cells 
can also interrupt DC maturation so that the DC 
cell can not be a potent APC. This mechanism 
is a mechanism that protect our body against 
excessive immune response to self antigen.8
When the body fails to tolerate self antigen, 
then an immune response against the self 
antigen will develop, which is known as 
autoimmune reaction.6 Therefore, the stage 
of DC maturation has an important role in 
the tolerance and autoimmunity process. The 
DC maturation process, which convert DC 
from immature into mature form will change 
DC characteristics that initially capturing 
antigens, but was not immunogenic becomes 
immunogenic. Immunogenic means that it 
can stimulate effector T cells (CD4, CD8) and 
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produce cytokines that support the next serial 
immune response (IFN-g).11
T-reg cells also have important role in 
the tolerance process against self antigen and 
become the key of balance in immune system, 
including in preventing autoimmune process. 
There are two types of T cells, CD4 regulator/
suppressor, i.e. the innate regulator T cell in the 
thymus gland, and several types of peripheral 
lymphocyte T cell (regulator T cell type 1 / 
Tr1, Th3 cell / cell mimicking Tr1 cell). Treg 
cell (TregCD24+CD25+) is produced naturally 
in the thymus gland. The cell can recognize 
foreign- and self-antigen and it is characterized 
by high expression of CD25. Natural Treg cell 
expresses CD25+ and Foxp3 in order to suppress 
the immune response, either by direct interaction 
among cells or by the assistance of IL-10 
cytokines or TGF-β. Tr1 cell, which is produced 
in peripheral circulation from TCD24+CD25- 
cell, does not express Foxp3, but it can produce 
IL-10 cytokines and TGF-β, but it can be also 
suppressed by those cytokines. Th3 cell has 
immunosuppressive effect, which is mediated 
by TGF-β.8,13
The role of Treg cell in the tolerance and 
autoimmune process is never apart from its 
interaction with DC. Immature and mature 
DCs work on different types of Treg cells. The 
immature DC mainly exposes self antigen and 
produces or stimulates the production of IL=10 
and stimulates the differentiation of Tr1 cell, 
which produces IL-10. In contrast, mature DC 
during inflammation or infection will consider 
self antigen as foreign antigen (microorganisms). 
Mature DC will support the maturation and 
activation of Treg cell CD24+CD25+ naturally 
by expressing costimulatory molecules and 
stimulating the production of IL-12. The Treg 
cell CD24+CD25+ will then control the immune 
response which takes place due to stimulation on 
foreign antigen (microorganism) or self antigen. 
In normal condition, there is a mechanism of 
controlled immune response and therefore, there 
is no excessive activation.8
In autoimmune disease, including GD, 
thera are some triggering factors, such as 
inflammation, hormone changes and stress 
that will change the environment adjacent to 
DC into inflammatory environment filled with 
increased level of inflammatory cytokines. 
Therefore, in addition to antibody production, 
the activity of an autoimmune disease is often 
correlated with the concentration of inflammatory 
cytokines level produced by immune cells. Such 
environment will convert iDC into DC, which 
has immunogenic characteristics and therefore, 
can stimulate naïve T cells and induces a serial 
of adapative immune response.10
Based on the abovementioned discussion, 
it can be seen that in normal condition, DCs 
undergo maturation process in line with their 
migration and they are able to recognize self and 
non-self antigen. DCs can also control immune 
response against self and non-self antigen by 
stimulating or suppressing immune response 
so that unnecessary immune response will not 
develop. The process of DC maturation has 
important role on the tolerance and autoimmune 
process.
DENDRITIC CELL IN GRAVES’DISEASE
As a major APC that has important role on 
the early course of GD, DC has been studied 
for several times since 1988. In 1988, Kabel 
et al conducted a study to evaluate the profile 
of tDC in GD and compared it with normal 
thyroid gland. The study involved 13 specimens 
of thyroid glands obtained from GD patients 
who had undergone surgery. It also evaluated 9 
specimens of normal thyroid glands (6 specimens 
were obtained from laryngectomy performed for 
laryngeal tumor and 3 specimens were collected 
from autopsies).
Immunohistochemical assay was done 
using several monoclonal antibodies, including 
OKIa (class II MHC), RFD1 (active DC), L25 
(DC and B cell), RIV4 (suppressor/cytotoxic T 
cell), Leu3ab (Th cell), FK24 (C3bi receptor, 
dominating myeloid cell, CD11b). OKT6 
(Langerhans cells) and CLB-RAG35 (factor 
VIII, von willebrand factor). The  study results 
showed that normal human thyroid gland 
contained fewer population of cell with single 
nucleus (mononuclear cell, MNC), which gave 
a strong positive reaction to MHC class II 
marker and its morphology was similar to DC, 
but it did not exert any reaction to RFD1 and 
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L25 markers. The RFD1 and L25 markers are 
the markers of DC characteristics in secondary 
lymphoid organs, which generate active reaction 
to immune response. It indicates that there are 
few of DCs in normal thyroid tissue, but they do 
not have active reaction to immune response and 
antigen processing. These DCs have a function 
on eliminating foreign material and damaged 
thyroid antigenic material to be drifted away to 
the lymph nodes. In thyroid glands of patients 
with GD, the number of DC is greater and the 
cells give positive reaction to RFD1 and L25 
markers that show active DC to immune response 
including to process the Ag. Some tDCs even 
seemed to have interaction with lymphocytes 
in thyroid gland. These findings are consistent 
with the previous study in experimental animal 
(rats), which showed that there was an increased 
number of tDC and the process occurs prior to 
the emergence of anticolloid antibody in the 
circulation.14 It is akin to explaining the serial 
of general immunology process, i.e. tDC capture 
the intrathyroidal Ag (functioning as iDD) and 
then take the Ag to lymph nodes to be presented 
on T cells (functioning as DC). The process of 
DC migration is then followed by expansion and 
maturation of T cells and B cells in the lymphatic 
vessels and it even infiltrates the thyroid gland.3
The profile of DC in thyroid glands of 
patients with Graves’ disease was then studied 
by Molne et al using immunocytochemical assay. 
The study was aimed for detecting characteristics 
of cells in the thyroid gland expressing HLA-DR, 
in which the number of cells increased in GD 
and the cells were located adjacent to follicle 
epithelium. The study results demonstrated that 
in the thyroid gland of GD, there were cells, 
which exert positive reaction to RFD-1 and 
had DC morphology, which were seemed to 
have direct interaction with follicle epithelium. 
Considering that both HLA-DR and RFD-1 
are associated with the function of APC, direct 
interaction between DC and thyrocyte is an 
essential component in the autoimmune reaction 
of GD.15
Although it is not easy to isolate DC from 
nonlymphoid gland, Croizet et al have been 
successfully performed DC culture on pig thyroid 
glands in 2000. In their study, they found 2-3% 
DC population of all pig thyroid cell suspensions. 
The study utilized a monoclonal antibody as the 
DC marker, which was directed to have reaction 
against the human and porcine S100β species and 
HLA-DR (MHC class II) and mannose receptors 
that were found to react with human species. 
Thyroid derived DC in the culture demonstrated 
immature DC as they express MHC class II that 
have a function to capture antigen. In 48 hours 
after the administration of TNF-α cytokines, 
almost 70% of immature DC converted to mature 
DC. The process of DC maturation in thyroid 
gland, in several aspects, is different from DC 
culture derived from precursors.16
Based on a preliminary study conducted 
by Kabel et al, we know that the number of 
intrathyroidal monocytes and dendritic cells 
(originated from monocyte precursors) is higher 
compared to healthy individuals. Dendritic cells 
also seemed to have a close interaction with 
lymphocytes; therefore, it showed the active 
characteristics of those cells in autoimmune 
process of Graves’ disease. Tas et al conducted 
a study to have further detailed evaluation 
the condition of monocytes and dendritic in 
peripheral circulation of patients with Graves’ 
disease, particularly in terms of polarization of 
monocytes and the development of clustering 
dendritic cells. Monocyte polarization is a 
process preceding the monocyte chemotaxis and 
in the study, it was evaluated by studying the 
change of monocyte morphology. While dendritic 
cells clustering as a response to allogeneic 
lymphocytes based on the number of formed 
clusters, i.e. one cluster usually consisted of 4-25 
dendritic cells. Defects in monocyte polarization 
and dendritic cell clustering were reported 
to occur in diseases such as chronic purulent 
rhinosinusitis and in immunodeficiencies in 
cancers. Those defects are correlated with the 
presence of a low molecular weight factor 
(LMWF), a nonspecific immunoregulator which 
structurally resembles to p15E, a protein of 
retro virus. The study found a low number of 
polarized monocytes in patients with Graves’ 
disease compared to those in the healthy group 
(mean value of 16% (9) vs 37% (8); p<0.01). 
Moreover, the formation of dendritic cell 
clustering in patients with Graves’ disease is also 
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lower than dendritic cell clustering in the healthy 
group (60 vs 151, p<0.01). Defects in monocyte 
polarization and dendritic cell clustering are 
probably caused by a p15E-like protein, which 
has immunosuppressive characteritics. They 
assumed that this factor occurred as a contra 
regulator mechanism of increased intrathyroidal 
immune response.17
The results of study is confirmed by 
Quadbeck(18) 14 years later, who observed 
some types of DCs in thyroid glands of patients 
with GD. The Quadbeckl study involves 
thyroid glands from 15 patients with GD who 
had undergone surgery. Monoclonal antibody 
markers used in the study are CD4 marker 
(T4, Leu-3) (CD4), markers for Th cell / DC 
type, monocytes, macrophage (CD40, CD50, 
gp50, ICAM-3), markers for DC, monocytes, 
granulocytes, T cells and B cells (CD54, ICAM-
1), markers for cells activated by cytokines 
(CD80, B7.1, BB1), markers for DC, activated 
B cells and macrophage (CD83, HB15), markers 
for DC, Langerhans cells, B cells (weak) (HLA-
DR, -DP and –DQ) and facultative markers by 
epithelial cells (RFD1). The study results show 
that three populations of tDC were found, i.e. 
1) immature tDC (MHC-II+/CD40-/CD80-) 
located in perifolicular area of the thyroid gland; 
2) partially mature CD80+ tDC in the connective 
tissue and interstitial cluster and 3) mature tDC 
(MHC II+/CD40+/CD80+/ RFD1+) in the 
cluster and adjacent to / interact with activated 
Th cells (CD4+/ MHC-II+).
Immature tDCs were also found in vein 
capillary vessels. The number of immature 
tDC in patients with GD is greater compared 
to healthy subjects and patients with toxic 
adenoma (toxic goiter, TG), i.e. 95%; 55% and 
51%, respectively. This phenomenon finding 
indicates that tDC in some patients with GD has 
experience maturation in the form of clusters 
(groups), which resemble to lymphoid tissue. It 
is confirmed further by the expression of MHC 
class II, CD40, CD50, CD80 dan RFD1 of the 
tDC. The maturity of tDC in the cluster is also 
confirmed by a strong interaction between tDC 
and CD4+/MHC class II of Th cells. Increased 
expression of HLA-DR in thryocytes probably 
indicates the presence of collaboration between 
DC, macrophage and thyrocytes to induce 
autoimmunity in GD.18
The correlation between DC, thyrocytes 
and the effect of TSH stimulation has also been 
studied by Croizet et al who conducted DC 
culture along with thyrocytes in an experimental 
animal study. After 8 days, the DC population in 
the culture, due to the presence of TSH, increases 
2-3 folds; while the number of DC population 
withouth TSH has reduced 75%. Moreover, with 
the presence of TSH, DC expresses mannose 
receptor and MHC class II on the cell surface. 
But when there is no TSH, DC does not express 
mannose receptor and MHC class II after the 
second day of culture. A large population of DC 
without any thyrocytes can not respond to TSH. 
The study indicates the role of TSH, the main 
signal for growth and differentiation of thyroid 
cells, to control the development and functional 
changes of thyroid-derived DC (DC that is 
found together with thyroid cells). The regulator 
function of TSH on DC requires the presence 
of thyrocytes. GM-CSF and TGFβ produced 
by thyrocytes are the intermediate cytokines 
between thyrocytes and DC in response to TSH. 
The study also showed that thyrocytes maintain 
the immature population in the thyroid gland.19
The DC profile in peripheral circulation and 
its correlation with Treg cells in GD has been 
studied by Mao et al. The study involved 77 
patients with untreated Graves’ Disease (uGD), 
13 patients with GD who had achieved euthyroid 
level using antithyroid agents (euthyroid Graves’ 
Disase, eGD), 15 patients with HT and euthyroid 
level (euthyroid hashimoto, eHT) and 74 subjects 
in the healthy control group. For Treg cells 
marker, they used CD4+CD25hiFoxp3+. The 
study showed that compared to the control group, 
the proportion of Treg cells in uGD group was 
lower (1.57±0.67% vs 3.36±0.96%; p<0.001); 
however, it did not apply for eGD group 
(2.98 ± 0.88%) and eHT group (3.09±1.02%). 
Although there was a reduced number, but the 
function of Treg cells in uGD was maintained. 
Moreover, the proportion of Treg cells was also 
negatively correlated to the concentracion of 
TSHR antibody level in uGD (r=0.735; p<0.001). 
The proportion of costimulatory molecules 
of CD86, CD80 and CD40 increased in uGD 
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compared to the control group. Untreated GD 
(uGD) had the highest proportion of pDC 
significantly compared to the control group 
(41.95±8.39% vs 32.85±8.02%; p<0.001),  eGD 
group (31.63±7.07%; p<0.001) and HT group 
(28.50±3.96%; p<0.0001). The highest ratio of 
pDC/DC was found in uGD compared to other 
groups and the ratio had negative correlation to 
the Treg cell proportion (r=0.689, p<0.001). The 
phenomenon showed that DC profile converted 
to pDC in uGD, which might have role in reduced 
Treg cells. Plasmacytoid DC (pDC) is the main 
IFN-α producer; therefore, increased proportion 
of pDC would also elevate the concentration of 
IFN-α cytokines in uGD. The mechanism of 
reduced Treg cells in uGD is due to the process 
of apoptosis with IFN-α dependent mechanism. 
The study also indicated that T3 thyroid hormone 
will improve apoptosis of Treg cells in uGD. The 
Mao study may expand the horizon of knowledge 
on the mechanism of Treg cell defects in patients 
with Graves’ disease.20
While Mao studied about the changes of pDC 
and mDC proportion in autoimmune thyroid 
disease, including the Graves’ disease, Leskela 
studied the distribution of pDC in autoimmune 
thyroid disease.
The Leskela study involved 35 patients with 
GD, 49 patients with HT and 34 control subjects. 
The study demonstrated reduced number of 
pDC in peripheral blood vessels (particularly in 
patients with severe GD); but the number of pDC 
in the thyroid gland increased. Plasmocytoid DC 
has a role in the autoimmune disease course by 
increasing the production of IFN-α cytokines that 
may affect the maturation of immunogenic DC. 
Leskela showed that there was low expression 
of immune regulator molecule in patients with 
Graves’ disease (ILTs/CD85, PD-L1, PSGL-1 or 
CD69 and IDO); therefore, there was a defect 
on the regulating mechanism, which resulted 
in a defect on the activity of T regulator cells. 
Changes on the DC proportion and phenotype 
was considered as a contribution on the GD 
pathogenesis.21
The effect of thyroid hormone on DC 
profile in peripheral circulation has been studied 
by Dedecjus involving patients with thyroid 
carcinoma who had total thyroidectomy surgery 
(three years prior to the study).22 The study 
subjects had their thyroxine supplementation 
stopped for 5 weeks in order to achieve 
hypothyroid condition. After the first blood 
sampling, thyroxine supplementation was 
given again at the dose of 3-4.5 µg/kg/day. 
The second blood sampling was performed 
after 2-month thyroxine supplementation. The 
study was conducted to observe the effect of 
thyroxine on the distribution of DC subtypes in 
peripheral blood vessels, the capability of DC as 
APC (HLA-DR), to evaluate the costimulatory 
molecules (CD40, CD80 and CD86) as well 
as DC maturation (CD83) in peripheral blood 
vessel. The study results indicated that the 
thyroxine supplementation during hypothyroid 
state (mean TSH 57.06±20.03 mIU/L) would 
increase both DC subtypes (mDC and pDC) 
at post-supplementation period (mean TSH 
0.04±0.029 mIU/L). Moreover, the percentage 
of DC expressing CD86 was higher and HLA-
DR expression increased in both DC types. T3 
supplementation increased CD86 expression in 
pDC.22
The early process of autoimmune in GD is 
initiated by self antigen exposure in the form 
of released TSH receptor component to the 
professional APC (DC). The APC will present 
the self antigen to T cells and subsequently 
stimulates B cells. Next, the B cells will produce 
antibody against TSH receptor. In untreated GD, 
there is a high proportion of plasmacytoid DC 
and therefore, it will increase the production of 
IFN-α, which has role in the apoptosis of regulator 
T cells. The reduced number of Tregulator cells 
in GD plays a role on the diminished control 
mechanism on B cell in antibody production.
The most recent study on DC profile in 
patients with GD was reported by Hassan I et 
al in 2013. The study compared the number of 
plasmocytoid DC between patients with GD 
and patients with non-autoimmune thyroid 
disease (struma multinodosa). It also compared 
the number of pDC in the lymph nodes of neck 
region and in the peripheral blood of patients 
with GD. The study results showed that there 
was a greater number of pDC in lymph nodes 
of neck region of patients with GD compared 
to the neck lymph nodes of patients with struma 
Dyah Purnamasari                                                                                                              Acta Med Indones-Indones J Intern Med
68
multinodosa. Moreover, there was a larger 
number of pDC in the neck lymph nodes of 
patients with GD than pDC in peripheral blood. 
It suggests that there was a migration and 
accumulation of pDC in the lymph nodes of neck 
region (draining lymph nodes).23
Several studies that have been conducted 
in patients with GD showed that the number 
of intrathyroid DC was greater in patients 
with GD compared to those with other thyroid 
diseases or with healthy individuals. Based 
on cytological perspective, we know that 
intrathyroid DC is active for immune response 
and has direct interaction with thyrocytes. In 
patients with GD, there was an increased ratio 
of pDC/cDC in peripheral circulation; while 
pDC is a main producer of IFN-α; therefore, 
there was also increased production of IFN-α, 
which has role in the apoptosis of T regulator 
cells. The low number of T regulator cells has 
a role in diminished control mechanism against 
B cell to produce antibody. In patients with 
GD, the number of pDC in peripheral blood is 
reduced; while the pDC number in the thyroid 
gland and lymph nodes adjacent to the thyroid 
gland increases. The expression of immune 
regulator molecules (ILTs/CD85, PD-L1, PSGL-
1 or CD69 and IDO) is reduced in patients 
with GD resulting in a defect of regulating 
DC and T regulator cells. Thyroid hormone 
supplementation in hypothyroid condition will 
increase the number of peripheral DC (cDC 
and pDC) and increase the expression of CD86 
and HLA-DR. Supplementation of T3 hormone 
in T reg cell culture in patients with untreated 
GD can increase the apoptosis of T reg cells. 
In the thyroid gland, the regulating function of 
TSH on DC requires the presence of thyrocytes. 
The thyrocytes will maintain DC in immature 
condition.
Several studies in patients with GD have 
demonstrated the DC profile in the thyroid 
gland and peripheral circulation, particularly 
in terms of pDC and cDC proportion. Different 
numbers of DC in the thyroid glands, lymph 
nodes and peripheral circulation, different types 
of peripheral DC and their correlation with 
the survival of T regulator cells, as well as the 
correlation between TSH, DC and thyrocytes 
have opened greater scope of knowledge on 
the role of DC in regulating GD autoimmune 
process, both directly and indirectly through the 
arrangement of regulator T cells. Essential role of 
DC in autoimmune process has enable us to think 
about autoimmune response modulation using 
DC in the therapeutical approach for autoimmune 
disease, including GD.3
CONCLUSION
In GD, there are changes of profile, the 
number and function of DC, both intrathyroid 
DC and peripheral DC. The changes of DC 
has indirectly affected immune response by 
suppressing T regulator cells.
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